<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02927717</url>
  </required_header>
  <id_info>
    <org_study_id>FL3b-Oss-2015</org_study_id>
    <nct_id>NCT02927717</nct_id>
  </id_info>
  <brief_title>An Italian Experience on Grade 3b Follicular Lymphoma</brief_title>
  <acronym>FL3b-Oss-2015</acronym>
  <official_title>An Italian Experience on Grade 3b Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab
      containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.

      Also an histological central review is planned in order to re-assess baseline diagnosis
      according to new 2016 World Health Organization (WHO) criteria.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>End of front-line treatment (evaluated from diagnosis up to 30 months)</time_frame>
    <description>Number of patients who achieve Complete Response or Partial Response after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>From first response to last follow-up for at least 2 years (up to 15 years)</time_frame>
    <description>Time from last response to nearest relapse or follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Date of last follow-up for at least 2 years (up to 15 years)</time_frame>
    <description>Time to last follow-up or death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Grade 3b Follicular Lymphoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient with grade 3b Follicular Lymphoma treated with Rituximab containing
        chemotherapy as front-line treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of grade 3b Follicular Lymphoma

          -  Age &gt; 18 years

          -  Front-line treatment with Rituximab containing chemotherapy

          -  Availability of histological sample for central review

        Exclusion Criteria:

          -  Other lymphoma diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Botto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOU Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Botto, MD</last_name>
    <phone>+390116334553</phone>
    <email>bbotto@cittadellasalute.to.it</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 28, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Barbara Botto</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Grade 3b Follicular Lymphoma</keyword>
  <keyword>2016 WHO Criteria</keyword>
  <keyword>Front-line treatment</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>paper publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

